Enliven Therapeutics, Inc. (ELVN)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$41.52-0.98%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Enliven Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.529
Annual ending 2026-12-31
Revenue	—	10,000
EPS	—	-1.857
Annual ending 2027-12-31
Revenue	—	5,000
EPS	—	-2.271

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain disciplined capital allocation including recent debt issuance	A supporting condition in Enliven Therapeutics, Inc.'s published investment case. The stated target is complete planned equity offering of ~8.9 million shares in 2026-Q2.	Intact	failure to complete planned capital raise	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 disclosures including 2026-Q2 financial results and a 2026-06-12 offering announcement. The company completed a $400 million upsized public offering in June 2026, increasing cash from $452 million at 2026-Q1 to $895 million at 2026-Q2, supporting disciplined capital allocation. The trajectory shows strong capital raising and balance sheet strengthening consistent with management's stated priorities. Delivery assessment Oct 24, 2026
Advance clinical development of therapeutic candidates	A primary condition in Enliven Therapeutics, Inc.'s published investment case. The stated target is achieve key clinical milestones in ongoing trials.	Improving	failure to meet expected clinical milestones or trial setbacks	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Control operating expenses to manage cash burn	A primary condition in Enliven Therapeutics, Inc.'s published investment case. The stated target is operating loss better than -$27.8M in next 4 quarters.	Intact	operating loss worsens beyond -$27.8M	Operating income: $-37.209M FY2026-Q2; GAAP. Published target: operating loss better than -$27.8M in next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-37,209,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4070aeaa-59e5-4f92-8e30-c23cec8fe384. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 consecutive quarters (2026-Q1 and 2026-Q2). Operating expenses increased moderately with R&D rising from $20.7 million to $29.0 million and G&A from $7.1 million to $8.2 million, reflecting ongoing clinical development costs. Management continues to control expenses relative to growth in activities, indicating a stable cost management trajectory. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.27

Unavailable → $-2.27 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$7,143	4 / 7
2026-07-25	Unavailable	$7,143	4 / 7
2026-07-26	Unavailable	$7,143	4 / 7
2026-07-27	Unavailable	$7,143	4 / 7
2026-07-28	Unavailable	$7,143	4 / 7
2026-07-29	Unavailable	$7,143	4 / 7
2026-07-30	Unavailable	$7,143	4 / 7
2026-07-31	Unavailable	$7,143	4 / 7
2026-08-01	Unavailable	$7,143	4 / 7
2026-08-02	Unavailable	$7,140	4 / 7
2026-08-03	Unavailable	$7,140	4 / 7
2026-08-04	Unavailable	$7,140	4 / 7
2026-08-05	Unavailable	$7,140	4 / 7
2026-08-06	Unavailable	$7,143	4 / 7
2026-08-07	Unavailable	$6,250	4 / 6
2026-08-08	Unavailable	Unavailable	4 / 3
2026-08-09	Unavailable	Unavailable	4 / 3
2026-08-10	Unavailable	Unavailable	4 / 3
2026-08-11	Unavailable	$6,250	4 / 6
2026-08-12	Unavailable	$6,250	4 / 6
2026-08-13	Unavailable	$7,140	4 / 7
2026-08-14	Unavailable	$6,250	4 / 6
2026-08-15	Unavailable	$6,250	4 / 7
2026-08-16	Unavailable	$6,250	4 / 7
2026-08-17	Unavailable	$6,250	4 / 7
2026-08-18	Unavailable	$6,250	4 / 7
2026-08-19	Unavailable	$6,250	4 / 7
2026-08-20	Unavailable	$5,556	4 / 7
2026-08-21	$-2.26	$5,556	5 / 8
2026-08-22	$-2.26	$5,556	5 / 8
2026-08-23	$-2.26	$5,556	5 / 8
2026-08-24	$-2.26	$5,556	5 / 8
2026-08-25	$-2.26	$5,556	5 / 8
2026-08-26	$-2.26	$5,556	5 / 8
2026-08-27	$-2.26	$5,556	5 / 8
2026-08-28	$-2.26	$5,556	5 / 8
2026-08-29	$-2.26	$5,556	5 / 8
2026-08-30	$-2.26	$5,556	5 / 8
2026-08-31	$-2.26	$5,556	5 / 8
2026-09-01	$-2.26	$5,556	5 / 8
2026-09-02	$-2.26	$5,556	5 / 8
2026-09-03	$-2.26	$5,556	5 / 8
2026-09-04	$-2.26	$5,556	5 / 8
2026-09-05	$-2.26	$5,556	5 / 8
2026-09-06	$-2.26	$5,556	5 / 8
2026-09-07	$-2.26	$5,556	5 / 8
2026-09-08	$-2.26	$5,556	5 / 8
2026-09-09	$-2.26	$5,556	5 / 8
2026-09-10	$-2.26	$6,250	5 / 8
2026-09-11	$-2.26	$6,250	5 / 8
2026-09-12	$-2.26	$6,250	5 / 8
2026-09-13	$-2.26	$6,250	5 / 8
2026-09-14	$-2.26	$6,250	5 / 8
2026-09-15	$-2.26	$6,250	5 / 8
2026-09-16	$-2.26	$6,250	5 / 8
2026-09-17	$-2.26	$6,250	5 / 8
2026-09-18	$-2.26	$6,250	5 / 8
2026-09-19	$-2.26	$6,250	5 / 8
2026-09-20	$-2.26	$6,250	5 / 8
2026-09-21	$-2.26	$6,250	5 / 8
2026-09-22	$-2.26	$6,250	5 / 8
2026-09-23	$-2.26	$6,250	5 / 8
2026-09-24	$-2.26	$6,250	5 / 8
2026-09-25	$-2.26	$6,250	5 / 8
2026-09-26	$-2.26	$6,250	5 / 8
2026-09-27	$-2.26	$6,250	5 / 8
2026-09-28	$-2.26	$6,250	5 / 8
2026-09-29	$-2.26	$6,250	5 / 8
2026-09-30	$-2.26	$6,250	5 / 8
2026-10-01	$-2.26	$6,250	5 / 8
2026-10-02	$-2.28	$5,556	6 / 9
2026-10-03	$-2.29	$5,000	6 / 9
2026-10-04	$-2.29	$5,000	7 / 9
2026-10-05	$-2.29	$5,000	7 / 9
2026-10-06	$-2.29	$5,000	7 / 9
2026-10-07	$-2.29	$5,000	7 / 9
2026-10-08	$-2.29	$5,000	7 / 9
2026-10-09	$-2.29	$5,000	7 / 9
2026-10-10	$-2.29	$5,000	7 / 9
2026-10-11	$-2.29	$5,000	7 / 9
2026-10-12	$-2.29	$5,000	7 / 9
2026-10-13	$-2.29	$5,000	7 / 9
2026-10-14	$-2.29	$5,000	7 / 9
2026-10-15	$-2.29	$5,000	7 / 9
2026-10-16	$-2.29	$5,000	7 / 9
2026-10-17	$-2.29	$5,000	7 / 9
2026-10-18	$-2.29	$5,000	7 / 9
2026-10-19	$-2.29	$5,000	7 / 9
2026-10-20	$-2.29	$5,000	7 / 9
2026-10-21	$-2.27	$5,000	7 / 10
2026-10-22	$-2.27	$5,000	7 / 10
2026-10-23	$-2.27	$5,000	8 / 10
2026-10-24	$-2.27	$5,000	8 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	9	0	0
2026-06-01	10	0	0
2026-07-01	10	0	0
2026-08-01	12	0	0
2026-09-01	12	0	0
2026-10-01	14	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 14 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

H.C. WainwrightOct 19 · prior Jul 9

$65.00 → $73.00+12.3%

Morgan StanleyOct 2

$70.00New observation · no comparable prior

$0$40.15$80.30

1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain disciplined capital allocation including recent debt issuanceDirect metric needs a verified mapping
Advance clinical development of therapeutic candidatesDirect metric needs a verified mapping
Control operating expenses to manage cash burnOperating income: $-37.209M

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-39.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Enliven Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-development company, not an established earnings compounder: it is loss-making, and recent financial performance is weak. The long-term thesis is in a watch state, with management’s progress on ELVN-001 mixed and overall evidence confidence low.

What's priced into Enliven Therapeutics, Inc.

The evidence does not provide a valuation comparison or a clear account of market expectations, so whether ELVN is cheap or expensive versus peers is unclear. No fragility gates fired, which suggests no specific fragility signal in this snapshot, but it does not establish that expectations are modest.

What the fundamentals likely do

Near term, losses and clinical-development spending are likely to continue; quarterly operating expenses rose as research and development advanced. Cash was $895 million at the end of 2026-Q2 after a June offering, while the planned Phase 3 ENABLE-2 start in the second half of 2026 or before year-end remains a key execution test. The August earnings miss and elevated industry miss risk add uncertainty, despite a stronger Healthcare sector backdrop.

What Enliven Therapeutics, Inc. hinges on

Over the next few quarters, the thesis hinges on whether management initiates ENABLE-2 on schedule and provides the planned regulatory and clinical updates while controlling cash use. Sector support could strengthen if VRTX, REGN, and MRNA continue to report strong results and guidance; misses or weaker guidance could weaken that tailwind. A further weakening in jobs data could also increase recession concerns for cyclical names.

Bottom line

For the 1-3 year view, ELVN remains a high-risk clinical-development story with meaningful cash resources but weak recent performance and key execution milestones ahead. The evidence is limited and low-confidence, so the thesis depends heavily on trial progress, spending discipline, and sector conditions. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.529
Annual ending 2026-12-31
Revenue	—	10,000
EPS	—	-1.857
Annual ending 2027-12-31
Revenue	—	5,000
EPS	—	-2.271

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.27

Unavailable → $-2.27 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$7,143	4 / 7
2026-07-25	Unavailable	$7,143	4 / 7
2026-07-26	Unavailable	$7,143	4 / 7
2026-07-27	Unavailable	$7,143	4 / 7
2026-07-28	Unavailable	$7,143	4 / 7
2026-07-29	Unavailable	$7,143	4 / 7
2026-07-30	Unavailable	$7,143	4 / 7
2026-07-31	Unavailable	$7,143	4 / 7
2026-08-01	Unavailable	$7,143	4 / 7
2026-08-02	Unavailable	$7,140	4 / 7
2026-08-03	Unavailable	$7,140	4 / 7
2026-08-04	Unavailable	$7,140	4 / 7
2026-08-05	Unavailable	$7,140	4 / 7
2026-08-06	Unavailable	$7,143	4 / 7
2026-08-07	Unavailable	$6,250	4 / 6
2026-08-08	Unavailable	Unavailable	4 / 3
2026-08-09	Unavailable	Unavailable	4 / 3
2026-08-10	Unavailable	Unavailable	4 / 3
2026-08-11	Unavailable	$6,250	4 / 6
2026-08-12	Unavailable	$6,250	4 / 6
2026-08-13	Unavailable	$7,140	4 / 7
2026-08-14	Unavailable	$6,250	4 / 6
2026-08-15	Unavailable	$6,250	4 / 7
2026-08-16	Unavailable	$6,250	4 / 7
2026-08-17	Unavailable	$6,250	4 / 7
2026-08-18	Unavailable	$6,250	4 / 7
2026-08-19	Unavailable	$6,250	4 / 7
2026-08-20	Unavailable	$5,556	4 / 7
2026-08-21	$-2.26	$5,556	5 / 8
2026-08-22	$-2.26	$5,556	5 / 8
2026-08-23	$-2.26	$5,556	5 / 8
2026-08-24	$-2.26	$5,556	5 / 8
2026-08-25	$-2.26	$5,556	5 / 8
2026-08-26	$-2.26	$5,556	5 / 8
2026-08-27	$-2.26	$5,556	5 / 8
2026-08-28	$-2.26	$5,556	5 / 8
2026-08-29	$-2.26	$5,556	5 / 8
2026-08-30	$-2.26	$5,556	5 / 8
2026-08-31	$-2.26	$5,556	5 / 8
2026-09-01	$-2.26	$5,556	5 / 8
2026-09-02	$-2.26	$5,556	5 / 8
2026-09-03	$-2.26	$5,556	5 / 8
2026-09-04	$-2.26	$5,556	5 / 8
2026-09-05	$-2.26	$5,556	5 / 8
2026-09-06	$-2.26	$5,556	5 / 8
2026-09-07	$-2.26	$5,556	5 / 8
2026-09-08	$-2.26	$5,556	5 / 8
2026-09-09	$-2.26	$5,556	5 / 8
2026-09-10	$-2.26	$6,250	5 / 8
2026-09-11	$-2.26	$6,250	5 / 8
2026-09-12	$-2.26	$6,250	5 / 8
2026-09-13	$-2.26	$6,250	5 / 8
2026-09-14	$-2.26	$6,250	5 / 8
2026-09-15	$-2.26	$6,250	5 / 8
2026-09-16	$-2.26	$6,250	5 / 8
2026-09-17	$-2.26	$6,250	5 / 8
2026-09-18	$-2.26	$6,250	5 / 8
2026-09-19	$-2.26	$6,250	5 / 8
2026-09-20	$-2.26	$6,250	5 / 8
2026-09-21	$-2.26	$6,250	5 / 8
2026-09-22	$-2.26	$6,250	5 / 8
2026-09-23	$-2.26	$6,250	5 / 8
2026-09-24	$-2.26	$6,250	5 / 8
2026-09-25	$-2.26	$6,250	5 / 8
2026-09-26	$-2.26	$6,250	5 / 8
2026-09-27	$-2.26	$6,250	5 / 8
2026-09-28	$-2.26	$6,250	5 / 8
2026-09-29	$-2.26	$6,250	5 / 8
2026-09-30	$-2.26	$6,250	5 / 8
2026-10-01	$-2.26	$6,250	5 / 8
2026-10-02	$-2.28	$5,556	6 / 9
2026-10-03	$-2.29	$5,000	6 / 9
2026-10-04	$-2.29	$5,000	7 / 9
2026-10-05	$-2.29	$5,000	7 / 9
2026-10-06	$-2.29	$5,000	7 / 9
2026-10-07	$-2.29	$5,000	7 / 9
2026-10-08	$-2.29	$5,000	7 / 9
2026-10-09	$-2.29	$5,000	7 / 9
2026-10-10	$-2.29	$5,000	7 / 9
2026-10-11	$-2.29	$5,000	7 / 9
2026-10-12	$-2.29	$5,000	7 / 9
2026-10-13	$-2.29	$5,000	7 / 9
2026-10-14	$-2.29	$5,000	7 / 9
2026-10-15	$-2.29	$5,000	7 / 9
2026-10-16	$-2.29	$5,000	7 / 9
2026-10-17	$-2.29	$5,000	7 / 9
2026-10-18	$-2.29	$5,000	7 / 9
2026-10-19	$-2.29	$5,000	7 / 9
2026-10-20	$-2.29	$5,000	7 / 9
2026-10-21	$-2.27	$5,000	7 / 10
2026-10-22	$-2.27	$5,000	7 / 10
2026-10-23	$-2.27	$5,000	8 / 10
2026-10-24	$-2.27	$5,000	8 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings